Please login to the form below
multiple sclerosis
This page shows the latest multiple sclerosis news and features for those working in and with pharma, biotech and healthcare.
Biogen reveals new data for MS therapies Tysabri and Vumerity
Biogen has announced new data for its multiple sclerosis therapies Tysabri and Vumerity, including analyses of extended interval dosing (EID) and new real-world experience data.
Latest news
-
Roche’s Ocrevus shows significant benefit in early-stage MS patients
New data for Roche’s Ocrevus has shown significant benefit in patients with early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS), the Swiss pharma announced last week.
-
Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
New post hoc data comes from phase 3 ASCLEPIOS trials. Novartis has revealed new post hoc data for its multiple sclerosis (MS) therapy Kesimpta only a few weeks after the drug ... months when compared to Sanofi’s Aubagio (teriflunomide) in a subgroup
-
Novartis gains EU approval for relapsing MS drug Kesimpta
The European Commission (EC) has approved Novartis’ Kesimpta for the treatment of relapsing forms of multiple sclerosis (RMS) in adults with active disease. ... The new EU approval for Kesimpta builds on Novartis’ existing presence in the therapy area
-
J&J’s multiple sclerosis therapy Ponvory moves closer to EU approval
Johnson &Johnson's (J&J) multiple sclerosis (MS) therapy Ponvory has moved closer to approval in the EU, after receiving a positive recommendation from the European Medicines Agency’s (EMA) Committee ... Relapsing forms of multiple sclerosis have
-
J&J’s MS drug ponesimod receives approval in the US
Johnson &Johnson’s (J&J) pharma division Janssen has announced that the US Food and Drug Administration (FDA) has approved its multiple sclerosis (MS) treatment ponesimod, under the brand name Ponvory. ... Every person with multiple sclerosis is
More from news
Approximately 95 fully matching, plus 511 partially matching documents found.
Latest Intelligence
-
What Hemingway got right about patient communications
as multiple sclerosis and migraine, to monitor their health and track the success of their medication.
-
The search for treatments for Parkinson’s disease
and a decade as senior director of neurodegenerative diseases research at Merck Serono where he served as its leader for in vitro pharmacology in neurology, including in multiple sclerosis, Parkinson’s
-
Cortellis Drugs to Watch in 2020 report
of B and T cells outside the lymph nodes, to treat relapsing forms of multiple sclerosis. ... Despite the expectation that it will face intense competition in the crowded multiple sclerosis market, sales of $80m are forecast for this year, rising to
-
20 for 2020 – Five pharma companies to watch
Elsewhere, BMS will need new Celgene prospects like selective JAK2 inhibitor Inrebic (fedratinib) – the first new myelofibrosis therapy in a decade – as well as other new drug candidates like multiple sclerosis ... The following month J&J agreed to a
-
Case study: OptiMiSe for MS nurses
OptiMiSe was launched in 2016 to support Multiple Sclerosis Specialist Nurses (MSSNs) in the provision of individualised care to patients living with MS.
More from intelligence
Approximately 0 fully matching, plus 37 partially matching documents found.
Latest appointments
-
Ex-Roche CMO Sandra Horning joins Gilead’s board of directors
During her ten-year career at Roche, Horning helped to bring 15 new medicines to patients in a range of diseases, including cancer, multiple sclerosis, influenza and blindness. ... Sandra has significant industry expertise and vast experience in drug
-
Topas Therapeutics appoints chief development officer and chief medical officer
vice president, multiple sclerosis/neurology and immunology.
-
GW Pharmaceuticals strengthens research and development team
Knappertz has previously held several leadership positions including vice president of clinical development for multiple sclerosis, oncology and biosimilar products at Teva, and numerous clinical and medical roles at Bayer and
-
Sanofi appoints Bill Sibold to lead its Genzyme business
Previously head of Sanofi Genzyme’s multiple sclerosis, oncology and immunology organisation, Sibold has experience in leading global therapy launches.
-
Dr Irina Antonijevic joins vasopharm
Most recently, Dr Antonijevic served as global head of early development in neurology, multiple sclerosis and ophthalmology at Sanofi Genzyme in the US.
More from appointments
Approximately 0 fully matching, plus 25 partially matching documents found.
Latest from PMHub
-
Covid-19: how is it affecting prescribing patterns?
Multiple sclerosis. Multiple sclerosis presents a more challenging story for pharma. ... They would not have been able to be given to multiple sclerosis patients during the initial phase of the pandemic and this is reflected in the patterns across our
-
Aurora celebrates 15 years of improving lives
It has:. Turned around NICE decisions. Added products to guidelines. Successfully launched a number of healthcare “firsts”, including the first pill in multiple sclerosis and the first genetic modifier in cystic
-
The other side of … multiple sclerosis
In fact, improving activation (&outcomes) demands it. The other side of … multiple sclerosis. ... His sister has multiple sclerosis, or MS, an autoimmune condition with relapses that can leave her clinging to the floor in an effort to stop the world
-
Diversity in clinical trials needs to extend beyond COVID-19 vaccine trials
Multiple sclerosis (MS) is three times more common in women than in men.
-
September 2020: diversity and inclusion in clinical trials round-up
Our latest round-up takes a closer look at the different conditions where health disparities are present, such as more women living with multiple sclerosis (MS), and the cancer death rate
More from PMHub
Approximately 16 fully matching, plus 29 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Account Management
-
Competitive Salary Offered
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Senior & Principal Medical Writer
-
Competitive Salary Offered
-
Account Manager
-
Competitive Salary
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
-
Medical Editor
-
Competitive Salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Publications Director
-
Competitive Salary
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
-
Associate Account Director
-
Competitive Salary
-
Senior Account Executive
-
Competitive Salary
-
Senior Medical Writer
-
Competitive Salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- Merck & Co reveals plans for women’s health spinoff Organon
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- bluebird bio aiming to separate business units by year-end
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Single dose of COVID-19 vaccines ‘significantly’ reduces infections
- InSite Events™ selected as an honorable mention in Fast Company’s 2021 World Changing Ideas Awards
- THE HIDDEN LIFESAVERS: overdose prevention campaign launches nationwide
- Moderna’s booster vaccines increase neutralising antibodies against COVID-19 variants
- FDA approval for Keytruda/Herceptin combination in first-line advanced gastric cancer
- US backs proposal to waive IP protection for COVID-19 vaccines
- Nanobiotechnology, Artificial Intelligence, and Virtual Care
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- How can we strike the right balance between familiarity and innovation when it comes to data presentation?
- Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
- Deep 6 AI: the smart software breathing new life into clinical trials
- Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
- COVID-proof: How Teams are Creating Launch Intensity thru Adversity
- Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....
